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Abstract Injuryof an arterial vesselwall acutely triggers amultifacetedprocessof thrombus formation,which isdictatedby thehigh-
shear flowconditions in the artery. In this overview,wedescribe how the classical concept of arterial thrombus formation
and vascular occlusion, driven by platelet activation and fibrin formation, can be extended and fine-tuned. This has
become possible because of recent insight into the mechanisms of: (i) platelet-vessel wall and platelet–platelet commu-
nication, (ii) autocrine platelet activation, and (iii) platelet–coagulation interactions, in relation to blood flow dynamics.
We list over 40 studies with genetically modified mice showing a role of platelet and plasma proteins in the control of
thrombus stability after vascular injury. These include multiple platelet adhesive receptors and other junctional mole-
cules, components of the ADP receptor signalling cascade to integrin activation, proteins controlling platelet shape,
and autocrine activation processes, as well as multiple plasma proteins binding to platelets and proteins of the intrinsic
coagulation cascade. Regulatory roles herein of the endothelium and other blood cells are recapitulated as well.
Patient studies support the contribution of platelet- and coagulation activation in the regulation of thrombus stability.
Analysis of the factors determining flow-dependent thrombus stabilization and embolus formation in mice will help to
understand the regulation of this process in human arterial disease.
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1. Introduction
At prevalent flow conditions, platelets interact only limitedly with the
healthy vessel wall, e.g. to maintain vascular integrity. However, this
changes dramatically at conditions of vascular inflammation, damage,
or disruption (situations leading to atherogenesis, haemostasis, or arter-
ial thrombosis, respectively), where platelets massively adhere to the
activated endothelium or the underlying endothelial matrix.1–3 In this
overview, we discuss shear-dependent mechanisms by which platelets
are capable to adhere to activated, damaged or disrupted arterial
vessels, and subsequently assemble into a stable or unstable throm-
bus.4,5 We describe how the classical concept of arterial thrombus for-
mation, developed almost 20 years ago, is currently extended and
fine-tuned due to better insights into the underlyingmolecular mechan-
isms in relation to blood flowdynamics.We illustrate how local changes
in fluid shear stress can control both platelet and coagulation activation
and, thereby, the growth and stabilization of a thrombus. Furthermore,
we recapitulate key roles of the vessel wall and leucocytes in the control
of thrombus formation. By comparing recently published studies, where
the effects of gene knockout have been determined on thrombus stabil-
ity and embolus formation in mouse, we provide a first encompassing
overview of the activation pathways in platelets and blood plasma that
may control these processes. Subsequently,wediscuss the possible clin-
ical relevance of these findings on flow-dependent thrombus stabiliza-
tion and embolization. For reasons of space, we only briefly touch the
processes of venous thromboembolism and fibrinolysis.
2. Classical concept of
flow-dependent platelet adhesion
and thrombus formation
How platelets adhere at a site of vascular activation or injury greatly
depends on the local blood flow and shear conditions. In the arterial
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system, themechanical force that is most relevant for platelet adhesion is
the shearstressof theblood.6 Since thevelocityofflowingblood is greater
in the centre of the artery than near the vessel wall, blood consists of con-
centric layers through the artery lumen that markedly differ in flow rate.
Shear stress is defined as the force per unit area between such layers,
and wall shear stress is the force per unit area applied onto the vessel
wall. Accordingly, also the shear rate (expressed as shear stress times
the viscosity of the blood) varies through the artery lumen from
minimal at the centre-line to maximal near the wall. Typical wall shear
rates are in the range of 300–800 s21 in large arteries, and of 500–
1600 s21 in arterioles of the microcirculation.6 Especially in stenotic
vessels, the wall shear rates can increase up to 10 000 s21 and even
higher.7 Wall shear rates in the venous part of the circulation are in
general low.
At a shear rate of.500 s21, initial tethering of platelets to the vessel
wall is primarily mediated by interaction of the receptor complex glyco-
protein (GP)Ib-V-IX to the von Willebrand factor (vWF). This multi-
meric adhesive protein is abundantly present in the plasma and
secreted by endothelial cells. It is also bound to locally activated endo-
thelium and deposits at the exposed extracellular matrix, particularly
binding to collagen fibres.8 At high wall shear rates (.5000 s21) or at
sharp gradients of shear rate, the interaction of GPIb-V-IX with the
vWF can be sufficient for unstable thrombus formation, albeit it
results in no more than weak intracellular signalling in platelets.9,10
Themarked shear gradients around stenotic sites, such as present in ar-
teries with advanced atherosclerosis, stimulate the endothelial release
of the vWF and trigger GPIb-V-IX-dependent thrombus formation.11
The initial, shear-dependent adhesion of platelets is possible due to
unique biomechanical properties of the vWF bond with GPIb-V-IX, as
this is characterized by a very rapid on-rate and facilitated by unfolding
of vessel wall-adhered vWF multimers.2 However, the bond between
GPIb-V-IX and vWF also has a rapid off-rate, implicating that by itself it
is insufficient for stable platelet adhesion, except in situations of quite
high-shear rate. The adhesion of platelets to vWF is stabilized by weak
activation of integrin aIIbb3, which mediates the integrin-dependent
binding of platelets to vWF, and also facilitates the binding to platelets
of plasma components such as fibrinogen and fibronectin.12,13 Interest-
ingly, GPIb-V-IX-dependent activation of aIIbb3 appears to be impaired
in platelets from mice lacking phospholipase D1 by a mechanism that
relies on reduced phosphatidic acid production.14,15
In both the human and mouse systems, platelet interaction with col-
lagen/vWF provides one of the most potent ways to attain stable adhe-
sion and to trigger platelet activation processes to thrombus
formation.3,12,16 The signalling in platelets occurs by way of interplay
between multiple receptors with, next to GPIb-V-IX and aIIbb3, the
immunoglobulin-family collagen receptor, GPVI, and the adhesive colla-
gen receptor, integrin a2b1.
17,18 Activation of platelets via GPVI, in
complex with the Fc receptor g-chain (FcRg), is mediated by a ‘signalo-
some’ of multiple proteins, including various adapter and scaffold
proteins (e.g. LAT, Cbl-b), tyrosine protein kinases (e.g. Syk),
phosphatidylinositol 3-kinases (PI 3-kinases), and small GTP-binding
proteins and their regulators (like Rac, Rho, CalDAG-GEFI).19 The
GPVI-induced signalling culminates in activation of phospholipase Cg2
(PLCg2), which produces second messengers causing an intracellular
release of Ca2+, followed by store-regulated influx of extracellular
Ca2+ via the Ca2+-sensor STIM1, and activation of downstream
protein kinases.20 Integrin a2b1, like other integrins interacting with
their substrates, strengthens and stabilizes the adhesion of platelets to
collagen.16,18 Platelets dispose of signalling mechanisms to tightly
synchronize the activation state—and thus adhesiveness—of their
various integrins.21 Under shear conditions, platelets can also arrest at
other extracellular matrix proteins, like thrombospondin-1, but the
ensuing signalling pathways are less intensively studied than for adhesion
to collagen/vWF.8,22
The shear-dependent adhesion and subsequent intracellular signalling
leads to a range of biochemical and morphological platelet responses.
Alterations in platelet shape occur via remodelling of the actin-myosin
cytoskeleton (via Rac1 and Rho-kinase pathways) and polymerization
ofmicrotubules (withRan-bindingprotein 10), resulting in the formation
of pseudopods and lamellipods after adhesion.23,24 Other prothrombo-
tic responses include enhanced activation of the various integrins, the
release of mediator molecules from platelet dense and alpha granules
(such as ADP, ATP, and Gas6), the formation of thromboxane A2, and
the scrambling of membrane phospholipids.3,15,25 These processes
achieve capturing of flowing platelets, thus leading to a growing platelet
aggregate,whereplatelets primarily interact via activatedaIIbb3 integrins
that bridge fibrinogen or fibronectin molecules. At high-shear condi-
tions, platelet–platelet interaction can also be achieved via GPIb-V-IX
interacting with vWF, bound itself to the platelet aggregate.26 Defects
in these activation pathways may lead to impaired haemostasis and
bleeding, as described in detail elsewhere.27
In the classical concept, the consolidationof a growing platelet throm-
bus is achieved by activation of the coagulation process. Blood coagula-
tion can be initiated by (extrinsic) tissue factor highly expressed at the
surface of subendothelial cells and, alternatively, by collagen and
platelet-derived polyphosphates, which trigger the (intrinsic) factor
XII pathwayof coagulation.28–30 Subendothelial tissue factor, particular-
ly on fibroblasts and smooth muscle cells, needs encryption before it
becomes active in coagulation, possibly through disulfide bond
changes by protein disulfide isomerase.3,31 Also tissue factor on micro-
particles can fulfil such a role.32 These initial processes can only become
effective if enforced in the propagation phase of coagulation, depending
on the exposure of pro-coagulant phospholipids, formed at the mem-
brane of platelets and other cells by a Ca2+-dependent phospholipid
scramblase.3,33 Thus, membranes with the surface expression of phos-
phatidylserine provide an active site for coagulation factor complexes
formation and thrombin generation.2,34 The generated thrombin pro-
duces fibrin fibres at the platelet surface, which are considered to stabil-
ize and consolidate the thrombus, and to mediate platelet-dependent
clot retraction.35,36 This fibrin network can trap flowing erythrocytes
and leucocytes, ultimately resulting in full-vessel occlusion.
This sequential scheme of arterial (occlusive) thrombus formation
explains why such a wide variety of drugs in use or in study can suppress
this process, i.e. blockers of: GPIb-V-IX (humanized antibodies), thromb-
oxane A2 formation (aspirin), P2Y12 receptors (clopidogrel, prasugrel,
ticagrelor), aIIbb3 integrins (abciximab, eptifibatide, tirofiban), thrombin
generation (anticoagulants), and protease-activated receptor (PAR)-
family thrombin receptors.37 However, as discussed extensively else-
where,minorormajor bleeding is a knownundesired side effect of essen-
tially all these drug types.15,27 This explains the still continuous search for
new targetsof antithrombotic drugs,where the riskofbleeding isminimal.
3. Vascular control
Discussed extensively elsewhere are the molecular processes by which
the healthy endothelium suppresses the coagulation process.3 The
thrombo-protective potential of vascular endothelial cells also extends
to preventing stable platelet adhesion and activation by a variety of
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mechanisms (Figure 1). The endothelial products nitric oxide and prosta-
cyclin (prostaglandin I2)bothact torelaxvascular smoothmusclecells and
inhibit platelet activation.38 Thus, in healthy endothelium, nitric oxide and
prostacyclin maintain a low blood pressure, reduce blood shear forces,
and suppressplatelet activation.Mousemodels confirm theantithrombo-
tic roles of both products. Hence, mice lacking endothelial nitric oxide
synthase show an impaired vasodilator response in conductance
vessels.Mousemodels, inwhichtheCOX2-dependent formationofpros-
tacyclin or its action is disrupted, present with a predisposition to throm-
botic events.39 Another platelet-inhibiting protein at the endothelial
surface is the ectonucleotidase CD39, which degrades (endothelial-
derived) ATP and ADP, and thus prevents platelet activation by these
nucleotides. Furthermore, the adenosine produced by CD39 has
anti-platelet activity.40 Clearly, these thrombo-protective effects of
the vessel wall are abolished upon local damage or disruption of the
endothelium.
A recent topic of interest is the role of vessel wall-adherent leucocytes
in thrombus formation. In certain mouse models, neutrophils can adhere
evenearlier thanplateletsuponvasculardamage,withasa result increased
tissue factor-dependent fibrin generation and platelet accumulation.41
Both neutrophils (forming neutrophil extracellular traps) andmonocytes
(exposing tissue factor) support the thrombotic process especially under
conditions of venous thrombosis.42,43 The relevance of these processes
for the development of arterial thrombosis is still unclear.
Figure1 Thrombus growth and instability in a damaged artery. (I) Endothelial activity at thehealthy vesselwall prevents platelet (Plt) adhesion. (II) Shear-
inducedadhesionof platelets at exposedsubendothelial collagen/vWFallowsplatelets to aggregate, partly in a reversibleway. (III)During thebuild-upphase
of a thrombus, small emboli are shed. (IV) In a grown thrombus containing contracted and fibrin-anchored platelets, local heterogeneities and blood flow
shear gradients allow the shedding of larger emboli.
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4. New concepts: dynamic,
fine-tuned regulation of thrombus
growth and stabilization
The classical scheme described above considers arterial thrombus for-
mation as a simple progressive process, starting with platelet adhesion
and ending with occlusion of the locally activated or damaged vessel.
However, many experimental studies, either in vivowith experimentally
damaged arteries in mice, or in vitro with flow chambers perfused with
whole-blood, point to a more complex organization of the thrombosis
process in time. In themacro-circulation (carotid artery) and themicro-
circulation (mesenteric and cremaster arterioles), it is often examined
that single platelets can adhere and detach during the build-up phase
of a thrombus. Furthermore, once a discernible thrombus has been
formed, it contracts and tends to shed smaller or larger emboli for a
certain period of time (Figure 1). Accordingly, flow-dependent dynamics
of platelet detachment, embolus shedding, and unstable occlusion seem
tobecommonevents during theprocessof thrombus formation.A large
number of studies with genetically modified mice point to the involve-
ment of many platelet-derived and coagulant proteins in the dynamic
regulation of the stability of thrombi formed at arterial flow conditions
(Table 1). Hence, the classical concept of thrombus formation needs
adjustments accommodating the flow-dynamic components. Refine-
ments, particularly, explaining the dynamics and heterogeneities of
thrombus build-up and fate, are described below. Participation of
vascular- or leucocyte-derived proteins in the control of thrombus sta-
bility has hardly been described in the literature.
4.1 Integrin aIIbb3 activation and reversible
platelet aggregation
Impaired or diminished activation of plateletaIIbb3 is known to cause in-
stability of thrombi, which are formed under flow in vivoor in vitro, and to
stimulate the detachment of single platelets and small aggregates.44,45 In
vitroobservations support the notion thataIIbb3 activation is a reversible
process, and that persistent signalling in platelets is required to keep this
integrin in an activated, pro-adhesive conformation.46 Several autocrine
and paracrine (between platelets) signalling processes appear to con-
tribute to persistent integrin activation, and many of these have been
shown to be involved in thrombus stabilization. A prominent factor is
the release of ADP and its interaction with platelet P2Y12 receptors,
which stimulates integrin activation via a pathway involving PI 3-kinase,
Akt2, Rap1b, and filamin A (Figure 2).46–49 Enforced integrin activation
is furthermore achieved by interaction of CD40L with its supposed
ligandCD40, bothofwhich aremembraneproteins that regulate throm-
bus stability.50 Another mechanism for continued integrin activation is
provided by interaction of the soluble molecule Gas6 (present in
plasma and limitedly stored in platelets) with the platelet TAM recep-
tors, Tyro, Axl, and Mer.51–53 New data yet suggest that plasma Gas6
may also stimulate the coagulation process by regulating the expression
of vascular tissue factor.54
Limited integrin activation also explains why, at gradients of shear
stress, platelets tend to loosely adhere to a growing thrombus via
GPIb-V-IX in an often instable way.10 Another family of proteins that is
considered tomodulate platelet integrin function is provided by the tet-
raspanins, of which TSSC6 and CD151 are abundantly expressed in the
plateletmembrane. Tetraspanin control ofaIIbb3 activationmay explain
why the genetic ablation of TSSC6 or CD151 results in thrombus in-
stability and increased embolus formation.55,56
Another mechanism controlling the activation of aIIbb3 and other
integrins is by redox control of free-cysteine thiols in the extracellular
chains, particularly by the protein disulfide isomerase.57 How the
redox control affects thrombus stabilization is still unknown.
4.2 Contact-dependent signalling to tight
platelet interactions
Particularly, the work of Brass et al. has led to substantial insight into
so-called contact-dependent activation pathways, by which platelets
can tightly interact with each other in a thrombus.5,58
Contact-dependent signalling occurs by pairs of ligands and recep-
tors, such as ephrinB1-EphA4 (which enforcesaIIbb3 activation andpre-
vents platelet disaggregation), and semaphorin 4D-plexin (which
supports Syk-mediated platelet activation); as well as by tight plate-
let–platelet interactions through JAM- and SLAM-family members.5,59
Deficiency in several of these proteins has been found to impair the sta-
bilization of mouse thrombi formed in vivo (Table 1). Jointly, these inter-
action establish close platelet–platelet contacts, which is considered to
be a requirement for the stabilizing contractionof platelets in the throm-
bus core.58 Inside platelets, signalling via Rho-kinase tomyosin and actin
appears to be a key mechanism transmitting the contractile forces from
the cell surface to the cytoskeleton.60 This may explain why arterial
thrombi in mice lacking RhoA or myosin heavy chain-9 are characteris-
tically unstable and show frequent embolization.23,61
A different set of contact receptors has been identified that negatively
regulates platelet activation and thrombus stability. In mice, the absence
of theCEACAM1or ESAMreceptors resulted in an increased thrombus
growth and reduced embolus shedding.62,63 It is hence tentative to
suggest that, within a thrombus, local balances of the platelet-activating
and platelet-inhibiting contact signalling events determine which part of
the thrombus can contract to form a stable plug, and which part of the
thrombus does not contract and is susceptible for detachment of
single of aggregated platelets. Intra-thrombus differences in contact-
dependent signalling may also explain the reported heterogeneity
within a thrombus with contracted, pro-coagulant, and loosely aggre-
gated platelets.64 However, as described above, also the partial penetra-
tion of thrombin and fibrin into a thrombus may contribute to this
heterogeneity.
A negative role in thrombus stability has also been observed for the
contact protein, connexin 37.65. This is a gap junction protein expressed
in platelets, as well as in endothelial cells, smooth muscle cells, mono-
cytes, and macrophages.65–67 Interestingly, the conclusions from the
twopublications regarding the role of connexin 37 in platelets are differ-
ent: one research group concludes that it functions by limiting platelet
activation and thrombus stabilization,65 while the other group finds
that it promotes platelet activation.67 An approach to take this further
would be the generation of mice lacking connexin 37 only in platelets.
4.3 Multisided regulation by coagulation
Theroleofcoagulation in thrombus formationandstabilizationappearsto
be more complex than earlier thought. Thrombin that is formed at the
thrombus surface contributes to platelet activation by interaction with
PARs.68,69 Recent evidence suggests that the contribution of PARs to
platelet activation isdependenton thebloodflowrate.WhereasPARs ac-
tivate platelets at low-shear conditions, their role becomes diminished at
pathologically high shear rates.70 Yet, thrombin-induced signalling contri-
butes to the generation of pro-coagulant PS exposing platelets, which are
abundantly formed in arterial thrombi.71There is ongoing research to find
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Table 1 Reported effects of genetic deficiency in mouse on embolization during arterial thrombus formation in vivo or in vitro
Genedefect MGI Protein defect Thrombosis Model Effect on arterial thrombus
formation
Emboli Ref(s)
Platelet receptors and membrane proteins
Axl 1 347 244 Axl (Gas6 receptor) Flow device Increased thrombus disaggregation + 53
Adra2a 87 934 a2 adrenergic receptor Mesentery/FeCl3 Increased formation of emboli + 95
Cd151 1 096 360 Tetraspanin CD151 Carotis/ligation, cremaster/
laser
Increased thrombus instability ++ 56
Cd40lg 88 337 CD40L Mesentery/FeCl3 Delayed occlusion, more unstable thrombi ++ 50
Fcer1g 95 496 FcR g-chain Carotis/ligation, cremaster/
laser
Smaller thrombi, more emboli formed + 76,96
Gp1ba 1 333 744 GPIba Carotis/ligation Smaller thrombi, reduced stable platelet adhesion ++ 97
Gp5 1 096 363 GPV Mesentery/FeCl3 Smaller thrombi, increased detachment ++ 98,99
Gp6 1 889 810 GPVI Carotis/FeCl3, ligation Smaller thrombi, reduced stable platelet adhesion ++ 100,101
Itga2 96 600 Integrin a2 Mesentery/FeCl3, flow device Smaller thrombi, more emboli formed + 75,102
Lat 1 342 293 LAT Cremaster/ laser Smaller thrombi, more emboli formed ++ 76
Mertk 96 965 Mer (Gas6 receptor) Flow device Increased thrombus disaggregation + 53
P2yr12 1 918 089 P2Y12 receptor Mesentery/FlCl3, cremaster/
laser
Smaller thrombi, more emboli formed ++ 47,103
Flow device Increased thrombus embolization ++ 103,104
Slamf1 1 351 314 SLAM (CD84) Mesentery/FeCl3 Delayed occlusion, more emboli formed + 59
Tspan32 1 350 360 Tetraspanin TSSC6 Mesentery/FeCl3 Increased thrombus instability + 55
Tyro3 104 294 Sky (Gas6 receptor) Flow device Increased thrombus disaggregation + 53
Ceacam1 1 347 245 CEACAM1 Mesentery/FeCl3 Larger thrombi, less emboli formed 2 62
Esam 1 916 774 ESAM Cremaster/laser Larger thrombi, less detachment 2 63
Gja4 95 715 Connexin 37 Mesentery/FeCl3\ Increased thrombus formation, less emboli 2 65
Platelet intracellular signalling proteins
Akt2 104 874 Akt2 Carotis/FeCl3 Smaller thrombi, increased instability ++ 105
Cblb 2 146 430 Cbl-b Carotis/FeCl3 Delayed occlusion, unstable thrombi + 106
Flna 95 556 Filamin A Flow device Increased platelet detachment + 107
Myh9 107 717 Myosin heavy chain-9 Carotis/FeCl3 Reduced thrombus growth, more emboli formed + 23
Plcg2 97 616 Phospholipase Cg2 Cremaster/ laser, flow device (smaller) thrombi, increased instability ++ 76,108
Prkaa2 1 336 173 AMPK-a2 Carotis/FeCl3 Less compact thrombus, more emboli formed + 109
Pik3cb 1 922 019 PI 3-kinase-b Flow device Increased thrombus disaggregation ++ 46
Pik3cg 1 353 576 PI 3-kinase-g Flow device Unstable thrombi, increased disassembly ++ 46
Rac1 97 845 Rac1 Cremaster/laser, flow device Increased instability of thrombi ++ 110
Ranbp10 1 921 584 Ran-binding protein 10 Mesentery/FeCl3 Reduced occlusion, unstable thrombi + 24
Rhoa 1 096 342 RhoA Mesentery/FeCl3 Reduced occlusion, more emboli formed ++ 61
Stim1 107 476 STIM1 Mesentery/FeCl3 Delayedocclusion, increasedplatelet detachment + 111
Plasma proteins
C3 88 227 Complement factor 3 Cremaster/photochemical Delayed thrombus formation, more emboli + 112
F11 99 481 Factor XI Mesentery/FeCl3 Increased detachment of thrombi + 80
F12 1 891 012 Factor XII Carotis/FeCl3, mesentery/FeCl3 Increased detachment of thrombi ++ 80,81
Fgg 95 526 Fibrinogen g-chain Carotis/FeCl3, mesentery/FeCl3 Increased detachment of thrombi ++ 113,114
Fn 95 566 Fibronectin Mesentery/FeCl3 Delayed formation of unstable thrombi ++ 115
Gas6 95 660 Gas6 Flow device Increased thrombus disaggregation + 53
Klk4 1 861 379 Prekallikrein Mesentery/FeCl3 Reduced thrombus formation, more emboli + 81
Lep 104 663 Leptin Carotis/FeCl3 Delayed occlusion, unstable thrombi + 116
Serpine1 97 608 PAI-1 Carotis/FeCl3 Longer time to occlusion, unstable thrombi + 117
Thbs1 98 737 Thrombospondin-1 Mesentery/photochemical Prolonged occlusion, more emboli formed + 118
Vtn 98 940 Vitronectin Carotis/FeCl3, mesentery/FeCl3 Longer time to occlusion, unstable thrombi ++ 117,119
Wvf 98 941 vWF Mesentery/FeCl3 (venules) Reduced thrombus formation, unstable + 120
Plg 97 620 Plasminogen Carotis/photochemical Shortened occlusion, less emboli 2 121
Indicated are the mouse genes, the corresponding proteins in blood platelets or plasma, the murine thrombosis model used (flow device in case of in vitro studies), the effect on embolus
formation (+, increased; ++, highly increased; 2, decreased).
MGI, mouse genome index.
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other strong agonists—besides thrombin—that can support collagen-
induced platelet activation (via GPVI). Currently in the spot light are the
CLEC-2 receptors, which via an unknown ligand, have been implicated
in arterial thrombus formation in mice.72 Such strong agonists other
than thrombin may also stimulate the contraction of platelets, making
an aggregate stable.60 On the other hand, fibrin clot retraction, mediated
via activatedaIIbb3 integrins, is still considered tobeamainmechanism for
platelet contraction in a stabilising thrombus.34
Although itmay be obvious that fibrin formation is needed for a stable
thrombus, reports on the effects of thrombin inhibitors in arterial
models in vivo primarily point to a reduced thrombus growth, rather
than to thrombus instability.73–76 A certain amount of fibrin formation
yet seems to be important, since in flow devices in vitro the inhibition of
fibrin polymerization resulted in shear-induced shedding of emboli.77
Mechanistically, these findings are not easy to explain. At the one
hand, the formation rates of thrombin and fibrin decrease at a higher
shear rate, as a consequence of thrombin dilution by blood flow,
which suggests that thrombin generation is a limiting factor in arterial
thrombus formation.69,78 At the other hand, neither thrombin nor
fibrin is uniformly distributed in an arterial thrombus,73,79 which may
imply that a consolidating fibrin network is only present in parts of the
thrombus.
Another relevant finding is that especially deficiencies in the intrinsic
coagulation pathway (prekallikrein, factor XII, or factor XI) reduce
thrombus stability and provoke embolus formation.80,81 In agreement
with this, pharmacological inhibition of the factor XII pathway results
Figure2 Key platelet and plasma proteins contributing to thrombus stability. (I) Platelet receptors and ligands involved in initial integrinaIIbb3 activation
and reversible platelet aggregation (see Table 1). The absence of these molecules increases thrombus instability. Also indicated is a box with intracellular
signalling proteins controlling this process. II. Contact-dependent signalling mechanisms implicated in platelet contraction and irreversible platelet aggre-
gation. Fibrin formed by the coagulation process stabilizes the platelet aggregate. (III) Plasma coagulation factors, via the intrinsic (factor XII, FXII) and ex-
trinsic (tissue factor,TF) pathways,mediating platelet-dependent thrombin andfibrin generation, stabilizing a growing thrombus.Also indicated is a primary
mechanism of platelet-leucocyte interaction via P-selectin and PSGL-1. See further Versteeg et al.3.
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in the formationof large emboli shed fromarterial thrombi.82 Thesedata
point to a thrombus-destabilizing effect upon partial—and likely non-
uniform—suppression of the clotting process within a thrombus.
More research is needed to understand the precise role of the intrinsic
coagulation pathway.
Interestingly, reports on the roles of anticoagulant proteins carried by
platelets do not describe effects on thrombus stability. For example,
tissue-factor pathway inhibitor located in platelets plays a significant
role in the control of thrombus growth, but was not reported to influ-
ence thrombus stability.83 The same is true for its cofactor, protein S
(Calzavarini, Angelillo-Scherrer, unpublished observations, 2012).
More thorough studies to the effect of genetic deficiency restricted to
mouse platelet proteins are needed to advance this field.
4.4 Disturbances in blood rheology
An aspect that is discussed extensively elsewhere,2 is the contribution of
bloodflow, and in particularof rheological disturbances, on the stabiliza-
tion or embolization of near-occlusive thrombi. When a stenotic or
otherwise vulnerable vessel tends to become occluded, high-shear gra-
dients are generated around the growing thrombus. These flow distur-
bances will not only accelerate platelet activation and fibrin formation,
but also provide the force for embolization of smaller or larger platelet
aggregates (Figure 1). Flow pulsations by the heart rhythm and vascular
distension may further aggravate the extent of embolization and
perhaps the size of the emboli, but this has hardly been investigated.
Another still poorly studied aspect is how red blood cells—either
flowing or when bound to fibrin fibres—contribute to thrombus stabil-
ity under arterial flow conditions.
5. Genetic mouse models and flow
chambers: key pathways of thrombus
(in)stability identified?
The above describedmechanisms point to involvement of a surprisingly
high number of proteins in the vessel wall, platelets, and the coagulating
plasma, that contribute to the formation and stabilization of an arterial
thrombus. Table 1 provides a list of experimental thrombosis studies
using mice, where effects have been measured of genetic modification
on stable platelet adhesion or shedding of emboli, following damage of
vessels of the macro-circulation (carotis artery) or microcirculation
(mesenteric or cremaster artery). The evidence for thrombus instability
comes from either intravital microscopic observations or rapid changes
in blood flow,measuredwithDoppler probes. Table 2 gives a list of drug
interventions that have been shown to influence thrombus stability in
vitro during the perfusion of the human blood through a flow device at
a high arterial shear rate.
As indicated in Table 1, for 44 different mouse genes a notable change
in stability of arterial thrombi has been reported. This list mostly con-
cerns genes and proteins that also play a role in the overall process of
thrombus growth. In short, referring to the mechanisms described
above, this concerns genes implicated in: (i) GPIb-V-IX and GPVI-
dependent platelet adhesion (also a2b1, FcR g-chain); (ii) GPVI-
mediated platelet signalling to Ca2+ rises and beyond (PLCg2, LAT,
Cbl-b, STIM1, Rac1); (iii) integrin activation (PI 3-kinases, Akt2, filamin
A, tetraspanins); (iv) autocrine and paracrine regulatory mechanisms
supporting integrin activation (P2Y12, CD40, CD40L, Axl, Mer, Sky,
SLAM); (v) andregulationof platelet contraction(RhoA,myosin). Further-
more relevant are genes of plasma proteins involved in: (vi) adhesion to
platelets (vWF, fibrinogen, fibronectin, vitronectin, thrombospondin-1);
(vii) activationof platelets (Gas6, leptin); and (viii) activationof the intrinsic
coagulation cascade (prekallikrein, factors XI, XII). Interestingly, hardly
any reports are available on thrombus instability due to specific platelet
secretion defects. A suppressive role is reported for negative regulators
of the contact activation (CEACAM1, ESAM, connexin 37).
The studies with human blood and flow devices to a certain extent
support involvement of the same platelet activation pathways in throm-
bus stability and embolization in the human system (Table 2). In particu-
lar, this concerns a role of theaIIbb3 activation pathway, in that inhibition
of P2Y receptors, PI 3-kinases, or the integrins themselves results in em-
bolization. Thrombus instability is also examined upon inhibition of
platelet contraction (EphA4, ephrinB1), Gas6 activity or fibrin forma-
tion. More work is clearly needed to demonstrate the importance of
the other proteins identified in mouse for the human system.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 2 Reported effects of pharmacological inhibitors on embolization of human thrombi under high-shear flow conditions in
vitro
Target protein Inhibitor Effect on thrombus formation ex vivo Emboli Ref(s)
Platelet proteins
EphA4/ephrinB1 Soluble fragments Increased platelet disaggregation + 122
Integrin aIIbb3 Abciximab, eptifibatide Increased platelet disaggregation + 123,124
Myosin heave chain-II Blebbistatin Increased thrombus instability + 125
P2Y1 / P2Y12 receptors MRS2179/ticagrelor/2-MeSADP Increased thrombus instability + 44,124,126
AR-C69931MX Increased platelet disaggregation + 46
PI 3-kinase-b TGX-221 Increased platelet disaggregation + 46
RhoA kinase Y-27632 Reduced thrombus formation, increased instability + 60,125
Plasma proteins
Fibrin polymer GPRP More unstable thrombi, releasing platelets + 77
Gas6 Depleted plasma Increased thrombus instability + 53
Perfusion studies of human blood flowed over collagen using flow devices. Indicated are the protein target, the inhibitor(s) use and the effect on embolus formation (+, increased).
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6. What can we learn more from
patient observations?
In man, thrombosis refers to the pathological condition where thrombi
form inopportunely in the lumen of vulnerable vessels, leading to inter-
ruption of blood flow, occlusion, and ensuing tissue damage. Antithrom-
botic drugs, which comprise antiplatelet, anticoagulant, and anti-
fibrinolytic drugs, are commonly used for the treatment and secondary
prevention of such thromboses in arteries and veins.2,37 The common
cause is rupture or erosion of an atherosclerotic plaque or a local dis-
turbance in haemodynamic shear forces in the flowing blood. Arterial
thrombosis, causing heart attacks, stroke, or limb gangrene, is respon-
sible for almost 50% of mortality in industrialized countries. Next to
treatments stimulating vasodilatation, antiplatelet drugs are the first
choice for treatment of (secondary) arterial thrombosis.84 It is relevant
to note here that non-steroidal anti-inflammatory drugs, particularly
those which inhibit COX2-dependent formation of prostacyclin in the
vessel wall, confer a cardiovascular hazard.39 Such drugs antagonize
the capacities of prostacyclin to suppress platelet activation and vaso-
constriction. This can predispose to thrombosis, hypertension, and
atherosclerosis.
Patientswith a transient ischaemic attack/stroke ormyocardial infarc-
tionmostly suffer fromthrombosis of the atherosclerotic carotid or cor-
onary artery. Such patients may present with symptomatic emboli that
are shed from the earlier formed thrombi. However, in case of acute
stroke or post-operatively after carotid endarterectomy, patients may
alsodevelopclinically asymptomatic embolization.85Asymptomatic em-
bolization has also been reported following carotid artery stenosis.86 In
such patients, shedding of platelet emboli from the thrombotic carotid
artery can be detected using trans-cranial Doppler ultrasound, for the
major part without pathological consequences.87 This indicates that
embolization is a frequent phenomenon after a thrombotic event that,
although often clinically silent, yetmay form an increased risk of becom-
ing symptomatic. More research is clearly needed to ascertain this.
Because of the reduced blood flow in the vein system, venous throm-
bosis relies more on thrombin and fibrin generation. Patients with
venous thrombosis or venous thromboembolism are treated with
several types of anticoagulants.88,89 Vitamin K antagonists produce
their anticoagulant effect by interfering with the g-carboxylation of
vitamin K-dependant prothrombin and factors VII, IX, and X. Unfractio-
nated heparins are indirect anticoagulants that bind to antithrombin,
enhancing its ability to inhibit activated factor X, thrombin, and other
coagulation factors. Low molecular-weight heparins and analogues
(danaparoid, fondaparinux) bind to antithrombin, and selectively po-
tentiate its anti-factor Xa activity. Drugs like lepirudin (also bivalirudin,
argatroban, dabigatran) are used as direct, selective inhibitors of throm-
bin, whereas the novel compounds rivaroxaban, apixaban, and edoxa-
ban are direct inhibitors of factor Xa. Whereas all these drugs have
proved to be clinically effective, there is hardly any knowledge on how
their action is determined by the local flow conditions at the site of
the thrombus.
An interesting case is provided by patients with specific coagulation
defects in the absence of bleeding. Patientswith afibrinogenaemia (com-
plete fibrinogen deficiency) sometimes develop thrombosis. The
thrombotic events can be located in either the arterial or venous terri-
tories.90 It is considered that in these patients thrombin that is formed is
more active, since it cannot be inactivated by binding to fibrin.91 One
of the consequences is increased platelet activation.92 The resulting,
fibrin-poor thrombi are described as large but loosely packed, confirm-
ing that fibrin provides thrombus stability.93 Interestingly, emboli are fre-
quently observed in these patients. Treatment comprises concomitant
infusion of fibrinogen and an anticoagulant, capable of binding fibrin-
bound and free thrombin, e.g. a direct thrombin inhibitor.
Severe factor XII deficiency may also provoke pulmonary emboliza-
tion, e.g. in John Hageman, the index patient with factor XII deficiency.
Epidemiological studies show a complex relation between severe
factor XII deficiency and increased thrombotic risk.94 One of the expla-
nations is that complete deficiency in factorXII restricts the formationof
fibrin, and facilitates symptomatic embolization in a similar way as
observed in murine studies. More translational research is required to
link these clinical observations to those of the mouse models.
7. Conclusions: the good and the bad
of arterial thrombus stabilization and
embolus formation
As described above, mouse experimental thrombosis studies in general
indicate that arterial thrombus growth and thrombus stability can be
linked processes.Many platelet and plasma proteins that control throm-
bus growth also appear to play a role in stabilization of the thrombus.
This is directly evident from intravital microscopy observations
showing that flow-mediated adhesion of platelets can be a reversible
event, and that single platelets aswell as small or large platelet aggregates
regularly detach from a thrombus even in wild-type mice. Hence, some
degree of instability may be considered as a natural phenomenon in
arterial thrombus formation. This is illustrated in Figure 1, schematizing
that during thrombus growth smaller and larger emboli are shed. The
limited clinical observations so far indicate that such shedding of
emboli also occurs in thrombotic human arteries.
On the other hand, thrombus growth and stability do not seem to be
controlled in exactly the same ways. For instance, there are surprisingly
few reports on a role of platelet secretion products in thrombus stabil-
ization (Table 1), whereas platelet secretion is considered to be major
determinant of thrombus growth. As schematized in Figure 2, key pro-
cessescontrolling the stabilityof a thrombus are (i) initial platelet integrin
activation controlling platelet aggregation, which can be reversible
resulting in shedding of platelet emboli; (ii) contact-dependent signalling,
stabilizing the platelet aggregates; and (iii) plasma thrombin and fibrin
generation via the intrinsic and extrinsic coagulation pathways, which
provides the thrombus with a fibrin network, but still allows shedding
of platelet-fibrin emboli (microclots).
In the clinical situation, the shedding of relatively large (fibrin-
containing) emboli may be most harmful, giving rise to (semi)occlusive
thrombus formation downstream in the vasculature. Clinically silent
likely are those emboli that are smaller and prone todisintegration. Pres-
ently,we can only speculate on themechanisms that favour the shedding
of large emboli with pathological consequences. An interesting hypoth-
esis is that these are due to local or temporal inhomogeneities in a
thrombus, e.g. differences in platelet contraction or local incomplete-
ness of fibrin formation. Thus, partial inhibition of ‘later’ pathways (irre-
versibly contracted platelets, platelet-fibrin clots) may result in emboli
that are not only larger, but also more stable themselves and clinically
symptomatic. Another possibility is that such emboli are formed by
partial thrombolysis due to restricted fibrinolytic activity. This clearly
needs further study. More thorough investigation is also needed to
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understand the roles of the natural platelet-inhibiting, coagulation-
inhibiting and fibrinolytic pathways in the control of flow-dependent
thrombus stability.
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